AdAlta Limited (ASX:1AD) is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology to generate a protein therapeutics with the potential to treat some of today’s most challenging medical conditions. Lead product AD-214 is in Phase 1 clinical studies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) (US$3b market) and other human fibrotic diseases. AdAlta also has a collaboration with multinational company GE Healthcare to discover i-bodies as diagnostic imaging agents for immuno-oncology.
Tim Oldham PhD
Managing Director & CEO
Dr Oldham became Managing Director and CEO of AdAlta in October 2019. He has 20 years experience building high growth life sciences businesses and business units in roles spanning business development, portfolio and product development, and commercialisation in Europe, Asia and Australia. His experience spans biologics, cell and gene therapies and pharmaceutical products. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer of cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira.